Navigation Links
High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis
Date:4/16/2010

Vienna, Austria, Friday 16 April: Results of a German study presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver .

NASH is a serious development of non-alcoholic fatty liver disease (NAFLD), the most common persistent liver disorder in western countries and for which there is no proven medical therapy. Results from this study show that high dose UDCA a naturally occurring bile acid, historically used to treat gallstones is not superior to placebo therapy. Moderate histological and biochemical improvement was only observed in a subgroup of mildly overweight male patients.

Commenting on the study, Professor Fabio Marra of the EASL scientific committee said: "The use of UDCA is still considered controversial in non-alcoholic hepatitis, although previous research has suggested that the treatment may have some beneficial effects. The results of this study indicate that high dose UDCA is not superior to placebo except in a small subset of individuals. Nevertheless, the results do provide some interesting clinical pointers for clinicians in this field."

In the study, patients with histologically proven NASH (n=186, 147 of whom proceeded to treatment) were organised according to gender, body weight, liver biochemistry and histology and were randomised to receive either 23-28mg/kg/d UDCA or placebo for a period of 18 months.

Pre- and post-treatment liver biopsies from 139 patients were analysed, the primary evaluation criteria was an improvement in liver histology and secondary criteria were improvements in NASH-associated histological findings and liver function test results.

No significant difference was seen in overall liver histology or biochemistries between the two treatment groups. Interestingly, beneficial results were seen in intra-acinar inflammation (inflammation of the functional units of the liver) and levels of the enzyme gamma glutamyltransferase (a marker for liver cell damage) in a small population of younger, mildly overweight males, indicating that UDCA therapy may be potentially useful for these patients.

The incidence and prevalence of NASH is increasing , in parallel with rising levels of obesity one of the main risk factors for NASH . With this in mind, it is important to identify effective treatment options to improve the management of patients and prevent progression to cirrhosis an irreversible condition with liver transplant the only definitive treatment.


'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Related biology technology :

1. Seattle Facial Plastic Surgeon Among First In The Nation To Offer Ultherapy™
2. Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine
3. Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
4. Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer
5. California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS
6. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
7. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
8. Progenitor Cell Therapy Expands Manufacturing Operations
9. Stroke Therapy with Corkscrew Device Most Beneficial, Study Suggests
10. Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries
11. Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... , ... July 17, 2017 , ... ... its long-standing innovation strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party ... areas – trait discovery, plant breeding, enabling technologies, biologicals and digital solutions. , ...
(Date:7/16/2017)... , ... July 16, 2017 , ... ... and analytical instruments announced the launch of its new line of Extreme Environment ... for applications that require CO2 and humidity for optimal cell growth such as ...
(Date:7/14/2017)... ... , ... Sonic Manufacturing Technologies is proud to be an ... system on its roof top. “We will be independent of the grid and ... The company’s proud history of social responsibility and participation in the preservation of ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC Maine ... has received US FDA 510 (k) clearance for use on Siemens Sysmex® CS-2500 ... Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample preparation, ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):